PAST PROJECTS

• 

  AMR in Sewage

  Using Sewage as a Surveillance Tool for Antimicrobial Resistance

• 

  AZD2816 (COV-Variant)

  A Phase II/III Partially Double-Blinded, Partially Randomised, Multinational, Active-Controlled Study to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2

• 

  COV009 Oxford Vaccine Study

  Post-approval follow-up for the COV001 and 002 trials, to determine the long-term safety and character of immunological response to the ChAdOx1 nCoV-19 coronavirus vaccine

• 

  Intestinal Microbiota in C. diff

  Role of the Intestinal Microbiota in Clostridium difficile infection and recurrence

• 

  COV002 Oxford Vaccine Study

  A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19

• 

  Discover

  A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection

• 

  Optimisation of HCV Therapy

  Developing a GP-led Hepatitis C Treatment Pathway

• 

  WISARD

  An Open-label, multi-centre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-Drug therapy with DTG/RPV FDC in Antiretroviral treatmentexperienced HIV-1 infected subjects virologically suppressed with Nnrtis Resistance Mutation K103N

• 

  Clover

  A Phase 3, Placebo-Controlled, Randomised, Observer-blinded Study to Evaluate the efficacy, safety, and tolerability of a clostridium difficile vaccine in adults 50 years of age and older

• 

  CHIPS+

  CHIPS+: Optimising the Health of Young People with HIV in their Transition from Paediatric to Adult Care

• 

  ARK

  Antibiotic Reduction and Conservation in Hospitals (ARK-Hospital)

• 

  TOPAZ-I (M14-423)

  An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

• 

  COV-COMPARE

  A Randomised, Observer-Blind, Controlled, Superiority Study to Compare the Immunogenicity Against COVID-19, of VLA2001 Vaccine to AZD1222 Vaccine, in Adults

• 

  Define AP3

  Define Appendix 3 (VST Therapy)

• 

  MIDAS

  Measuring the impact of Improved Diagnostics on Antimicrobial Stewardship in Respiratory Tract Infection

• 

  Odyssey

  Phase 1/2, randomized, observer-blind, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age

• 

  SUPERNOVA

  Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA)

• 

  NEXTCOVE

  A randomised, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283.222 administered as a booster dose compared with mRNA-1273.222 in participants aged 12 years and older for the prevention of COVID-19

• 

  PANORAMIC

  Platform Adaptive trial of NOvel antiviRals for eArly treatMent of covid-19 In the Community

• 

  DexEnceph

  Dexamethasone in Herpes Simplex Virus Encephalitis Randomised Controlled Trial and Non-HSV Cohort Study

• 

  VIBRANT

  Vaccine Immunity Breakthrough & Re-Infection – ANtibody & T-cells

• 

  IONOE

  Improving Outcomes of Necrotising Otitis Externa

• 

  TIDE

  A multi-centre, randomised controlled, non-inferiority and cost effectiveness trial comparing Polyhexanide and Chlorhexidine with Neomycin to Mupirocin for nasal methicillin-resistant Staphylococcus aureus (MRSA) decolonisation amongst adult hospital in-patients

• 

  HEAL-COVID

  HElping Alleviate the Longer-term consequences of COVID-19 (HEAL-COVID)